Current chemotherapeutic approaches for hepatoblastoma

International Journal of Clinical Oncology

Volumn 18, Issue 6, 2013, Pages 955-961

  Watanabe, Kenichiro ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Hepatoblastoma; Liver tumor; Pediatric oncology

Indexed keywords

ALPHA FETOPROTEIN; AMIFOSTINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PIRARUBICIN; VINCRISTINE;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HEPATOBLASTOMA; HIGH RISK POPULATION; HUMAN; INFECTION; LIVER TRANSPLANTATION; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; NORTH AMERICA; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; THROMBOCYTOPENIA;

CHILD; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FLUOROURACIL; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; PEDIATRICS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84891448451     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0616-8     Document Type: Review

References (22)

1. Katzenstein HM, London WB et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol 20(16):3438-3444
2. Exelby PR, Filler RM, Grosfeld JL (1975) Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American academy of pediatrics surgical section survey-1974. J Pediatr Surg 10(3):329-337
3. Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblastoma - results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36(11):1418-1425
4. Holton CP, Burrington JD, Hatch EI (1975) A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report. Cancer 35(4):1083-1087
5. Douglass EC, Reynolds M, Finegold M et al (1993) Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol: Off J Am Soc Clin Oncol 11(1):96-99
6. Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18(14):2665-2675
7. Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 24(18):2879-2884. doi: 10.1200/JCO.2005.02.6013
8. Malogolowkin MH, Katzenstein HM, Krailo M et al (2008) Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 26(14):2379-2383. doi: 10.1200/JCO.2006.09.7204
9. Malogolowkin MH, Katzenstein HM, Meyers RL et al (2011) Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. J Clin Oncol 29(24):3301-3306. doi: 10.1200/JCO.2010.29.3837
10. Malogolowkin MH, Katzenstein HM, Krailo M et al (2012) Treatment of hepatoblastoma: the North American Cooperative Group experience. Front Biosci 4:1717-1723
11. Trobaugh-Lotrario AD, Katzenstein HM (2012) Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies. Pediatr Blood Cancer 59(5):809-812. doi: 10.1002/pbc.24219
12. Palmer RD, Williams DM (2003) Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 41(1):78-80. doi: 10.1002/mpo.10300
13. Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 25(29):4622-4627. doi: 10.1200/JCO.2007.11.6103
14. Czauderna P (2012) Hepatoblastoma throughout SIOPEL trials - clinical lessons learnt. Front Biosci 4:470-479
15. Aronson DC, Schnater JM, Staalman CR et al (2005) Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 23(6):1245-1252. doi: 10.1200/JCO.2005.07.145
16. Perilongo G, Shafford E, Maibach R et al (2004) Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 40(3):411-421
17. Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361(17):1662-1670. doi: 10.1056/NEJMoa0810613
18. Zsiros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28(15):2584-2590. doi: 10.1200/JCO.2009.22.4857
19. Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14(9):834-842. doi: 10.1016/S1470-2045(13)70272-9
20. Sasaki F, Matsunaga T, Iwafuchi M et al (2002) Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 37(6):851-856
21. Hishiki T, Matsunaga T, Sasaki F et al (2011) Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 27(1):1-8. doi: 10.1007/s00383-010-2708-0
22. Otte JB, Pritchard J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42(1):74-83. doi: 10.1002/pbc.10376